MedPath

MEP and Neuromuscular Blocker

Not Applicable
Completed
Conditions
Brain Tumor
Interventions
Drug: Arm I (MEP)
Registration Number
NCT04768400
Lead Sponsor
Gangnam Severance Hospital
Brief Summary

It is important to predict the influence of the neuromuscular blocking agents on the motor evoked potential. Investigator will investigate the dose-response relationship between the degree of the neuromuscular blockade and the motor evoked potential in patients undergoing brain tumor surgery using the population approach. Investigator will investigate the influence of the other factors such as the impedence, reactance, muscel amount, and age on the motor evoked potential.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  1. Patients aged 19 years old or older, with American Society of Anesthesiologists Physical Status 1-3, and scheduled for elective brain tumor surgery under the monitoring of the motor evoked potential
Exclusion Criteria
  1. Central or peripheral neuromuscular disease
  2. Sensory or motor nerve disorder
  3. Allergy to propofol, remifentanil, and rocuronium
  4. Patients with pacemaker

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
rocuroniumArm I (MEP)Neuromuscular blockade will be performed using rocuronium.
Primary Outcome Measures
NameTimeMethod
Amplitude of the motor evoked potentialAt intraoperative 0 hr from the start of the anesthetic induction

Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the start of the anesthetic induction.

Secondary Outcome Measures
NameTimeMethod
Amplitude of the motor evoked potentialAt intraoperative 0 h from the opening of the dura

Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the opening of the dura.

Trial Locations

Locations (1)

GangnamSeverance Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath